Revolutionize the Development & Delivery of Gene Therapies for the Eye
More companies than ever before are realizing the potential of gene therapies to treat a wide range of ophthalmic disorders but in practice, there are still hurdles to overcome.
A variety of unique challenges must be addressed to effectively bring gene therapies to patients, from developing preclinical models that accurately translate to the clinic to validating clinical endpoints that will satisfy regulators.
Gene Therapy for Ophthalmic Disorders will unite industry leaders across the ophthalmology space virtually to overcome the specific delivery and drug development challenges faced by companies developing gene therapies for ophthalmic diseases.
Don’t get left behind. Join pioneering companies including Novartis, Gensight Biologics and Spark Therapeutics to revolutionize the treatment of ophthalmic diseases.
Access the official agenda for more information.
Attendees of other Gene Therapy Events Series meetings have said:
“Best conference of the year for gene therapy companies to understand how our industry is tackling the challenges of pioneering the development of our advanced therapy products.”
Sangamo Therapeutics
“Outstanding networking. A pleasure to find opportunities for cross-functional learning
amongst peers. High-quality speakers,
outstanding job.”
Neurogene
Proud To Partner With
Other Events in the Gene Therapy Series
